Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

M-100907 (Aventis).

¹Psychiatry Department, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. Tomas.dePaulis@mcmail.vanderbilt.edu

Current Opinion in Investigational Drugs (London, England : 2000)

|August 31, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Anxiolytic-like effects of DAIZAC, a selective high-affinity 5-HT(3) receptor antagonist, in the mouse elevated plus-maze.

Pharmacology, biochemistry, and behavior·2001

Same author

Pharmacological characterization of morphine-6-sulfate and codeine-6-sulfate.

Brain research·1999

Same author

Characterization of (S)-des-4-amino-3-[125I]iodozacopride ([125I]DAIZAC), a selective high-affinity radioligand for 5-hydroxytryptamine3 receptors.

The Journal of pharmacology and experimental therapeutics·1998

Same author

Characterization of desamino-5-[125I]iodo-3-methoxy-zacopride ([125I]MIZAC) binding to 5-HT3 receptors in the rat brain.

Progress in neuro-psychopharmacology & biological psychiatry·1998

Same author

Synthesis and 5-HT-3 receptor binding of 2- and 3-(halo)alkoxyl substituted (S)-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chlorobenzamides as potential radioligands.

Nuclear medicine and biology·1998

Same author

Synthesis and radiolabeling of (S)-4-amino-5-iodo-2-methoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamide, the active enantiomer of [125I]iodozacopride, and re-evaluation of its 5-HT3 receptor affinity.

Chemical & pharmaceutical bulletin·1998

Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011

Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010

Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010

See all related articles

M-100907, a selective 5-HT2A antagonist, shows promise in treating schizophrenia and other neurological disorders. Despite discontinuation for acute schizophrenia, its efficacy in animal models warrants further investigation for chronic conditions.

Area of Science:

Pharmacology
Neuroscience
Drug Development

Background:

M-100907 is a selective 5-HT2A antagonist developed for schizophrenia.
It has undergone phase III trials for chronic schizophrenia.

Purpose of the Study:

To evaluate the efficacy of M-100907 in treating schizophrenia.
To explore its potential in other neurological disorders.

Main Methods:

Preclinical studies using animal behavioral models of schizophrenia.
Clinical trials for chronic schizophrenia.

Main Results:

M-100907 demonstrated potent antagonism in animal models involving 5-HT2A receptor activation and NMDA receptor blockade.
Development for acute schizophrenia was discontinued due to poor results.

Related Experiment Videos

Conclusions:

M-100907 shows potential as a treatment for schizophrenia, particularly chronic forms.
Further research may explore its utility in other neurological conditions like autism and ADHD.